New clinical trials regulation in Spain: analysis of royal decree 1090/2015

The coming into force of Directive 2001/20/EC represented a step forward in harmonising clinical trial regulation in European countries, guaranteeing a uniform protection of subjects participating in clinical research across Europe. However, it led to a disproportionate increase in the bureaucratiza...

Full description

Saved in:
Bibliographic Details
Published in:Clinical & translational oncology 2017-03, Vol.19 (3), p.291-300
Main Authors: Martin Jimenez, M., Calvo Ferrandiz, A., Aparicio Urtasun, J., Garcia-Campelo, R., Gonzalez-Flores, E., Lazaro Quintela, M., Muñoz Mateu, M., Rodriguez Sanchez, C. A., Santaballa Bertran, A., Sepulveda Sanchez, J. M., Vera Garcia, R., Virizuela Echaburu, J. A., Segui Palmer, M. A.
Format: Article
Language:English
Subjects:
Clinical Trials as Topic - legislation & jurisprudence
Government Regulation
Humans
Medicine
Medicine & Public Health
Oncology
Spain
Special
Special Article
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The coming into force of Directive 2001/20/EC represented a step forward in harmonising clinical trial regulation in European countries, guaranteeing a uniform protection of subjects participating in clinical research across Europe. However, it led to a disproportionate increase in the bureaucratization, and thus, it became evident that procedures needed to be simplified without detriment to patient’s safety. Thus, Regulation 536/2014, that repealed Directive 2001/20/EC, with the aim of decreasing the growing bureaucratization and stimulating clinical research in Europe, established simplified procedures, such as regulating a common procedure for authorising trials in Europe, the institution of strict assessment timelines, or the definition of new concepts, such as “low-intervention clinical trial”. The legal form of a Regulation allowed the norm to be directly applied to Member States without the need for transposition. By means of the new Royal Decree, the national legislation is adapted to make the application of the regulation feasible and it allows the development of the aspects that the Regulation leaves to national legislation. Both documents seek to stimulate clinical research with medicinal products to foster knowledge, facilitate transparency, and reinforce subjects’ safety. This will surely be the case, but with this revision, we will look at the novelties and key aspects that are most relevant to investigators and we will analyse the consequences for all parties involved in clinical research.
ISSN:1699-048X
1699-3055
DOI:10.1007/s12094-016-1550-9